Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 2/20 | 0.49 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.49 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.49 |
| ▸ | GNAO1 | P09471 | 8/20 | 0.49 |
| ▸ | GNAI3 | P08754 | 7/20 | 0.49 |
| ▸ | GNAI1 | P63096 | 7/20 | 0.49 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24970676 | 0.98 | S1PR1 (0.46) | S1PR1S1PR3S1PR5GNAO1GNAI3 | |
| SCHEMBL23921701 | 0.92 | TSHR (0.44) | S1PR1S1PR3S1PR5GNAO1GNAI3 | |
| SCHEMBL347104 | 0.84 | TSHR (0.47) | S1PR1S1PR3S1PR5SIGMAR1TSHR | |
| SCHEMBL23767360 | 0.84 | S1PR1 (0.53) | S1PR1S1PR3S1PR5GNAO1GNAI3 | |
| SCHEMBL30150906 | 0.81 | TSHR (0.50) | S1PR1S1PR3S1PR5S1PR4SIGMAR1 | |
| SCHEMBL30150905 | 0.81 | TSHR (0.50) | S1PR1S1PR3S1PR5S1PR4SIGMAR1 | |
| SCHEMBL26894648 | 0.81 | GNAO1 (0.43) | S1PR1S1PR3S1PR5GNAO1GNAI3 | |
| SCHEMBL23767362 | 0.79 | S1PR1 (0.51) | S1PR1S1PR3S1PR5GNAO1GNAI3 | |
| SCHEMBL22859605 | 0.78 | S1PR1 (0.49) | S1PR1S1PR3S1PR5GNAO1GNAI3 | |
| SCHEMBL20442721 | 0.76 | TSHR (0.38) | S1PR1S1PR3S1PR5TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | S1PR1 2558/4885S1PR3 2249/4885S1PR5 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.